Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $23.6 million.

  • Gyre Therapeutics' Operating Expenses rose 1121.62% to $23.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.2 million, marking a year-over-year decrease of 4743.47%. This contributed to the annual value of $89.6 million for FY2024, which is 5041.29% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Operating Expenses is $23.6 million, which was up 1121.62% from $24.6 million recorded in Q2 2025.
  • Gyre Therapeutics' Operating Expenses' 5-year high stood at $124.0 million during Q4 2022, with a 5-year trough of -$51.5 million in Q2 2022.
  • For the 5-year period, Gyre Therapeutics' Operating Expenses averaged around $27.7 million, with its median value being $22.0 million (2024).
  • Within the past 5 years, the most significant YoY rise in Gyre Therapeutics' Operating Expenses was 44478.97% (2022), while the steepest drop was 34484.46% (2022).
  • Over the past 5 years, Gyre Therapeutics' Operating Expenses (Quarter) stood at $22.8 million in 2021, then surged by 444.79% to $124.0 million in 2022, then fell by 4.18% to $118.8 million in 2023, then plummeted by 77.09% to $27.2 million in 2024, then dropped by 13.11% to $23.6 million in 2025.
  • Its last three reported values are $23.6 million in Q3 2025, $24.6 million for Q2 2025, and $19.8 million during Q1 2025.